Open in interactive viewer → charts, metric popovers & call review

DocGo's Shrink-to-Win Turnaround Meets a $25 Million Market Cap

The microcap posted its first revenue increase since 2023, then trimmed guidance and lost its CEO—and the stock is down 62% in 90 days.
DCGO · Earnings Call · 2026-11-09

The quarter that wasn't supposed to be a cut

DocGo's Q3 2026 print had the makings of a real turn: revenue of $73.4 million, up 4% year over year and the first increase since Q2 2023; an adjusted EBITDA loss of $3.2 million versus $7.2 million a year ago; gross margin of 33.3%, up from 30.5% in Q2; and adjusted SG&A down to $28.7 million from $30.8 million in Q1. “Today, I'm pleased to report considerable progress on our path toward profitability. For the quarter, we generated revenue of $73.4 million and reported an adjusted EBITDA loss of $3.2 million, compared with losses of $6.3 million in the second quarter and $10.2 million in the first quarter.” — Lee Bienstock, Chief Executive Officer · 2026-11-09 Management even reaffirmed the full-year adjusted EBITDA loss of $17 million-$22 million. But it trimmed revenue guidance to approximately $300 million from $305 million-$310 million. The market focused on the cut. The stock is down 62% in the last 90 days, 68% from its August peak, and the whole company is now valued at $24.9 million. Total revenue The latest filed fundamentals still reflect the prior quarter—$73 million, down 9% year over year—so the call is the first clean read on the turn.

Shrinking the perimeter

The most important new theme on this call is not growth. It is Upstate New York, the company's top keyword for the quarter. DocGo is winding down its medical transportation business there, roughly $10 million of annual revenue, because it cannot get the market to a profitability threshold. Excluding Upstate New York, third-quarter transport gross margin would have been around 37% instead of 34.7%, and the market is expected to account for about $3 million of adjusted EBITDA loss this year that will not recur in 2027. That is the whole strategy in miniature: cut revenue to lift margin.Lee Bienstock framed the trade-off directly: “$240 million of the $300 million is EBITDA contribution positive. We do have $60 million that is weighing on the margin.” — Lee Bienstock, Chief Executive Officer · 2026-11-09 Of that $60 million, about one-third will be shut down and two-thirds restructured or renegotiated. The Care in the Home business is part of the same pruning. Visit volume fell 26% in Q3—deliberately—as DocGo pulled back outreach, shifted the clinician mix from LPNs to mobile phlebotomists and medical assistants, and used AI to automate scheduling. Management says Care in the Home should be positive on an adjusted EBITDA contribution basis late this year or early next, with a new Pennsylvania program using the same lower-cost model. That is a credible operating story. It is also a shrinking one. The revenue guide came down because management chose to give back unprofitable revenue, and the fourth-quarter implied revenue of $77 million-$78 million depends on seasonal SteadyMD and Care in the Home volume.

The cash clock is now the headline

The keyword rotation tells the story. Earlier in 2026, DocGo's top keywords were growth-facing: weight loss, new logos, online pharmacy, clinical staffing. This quarter, Available cash is a top-three keyword and cash burn is back in the top 15. Cash was $19.1 million at September 30, down from $25.2 million at June 30. The Perceptive term loan has replaced the asset-based line: $12.5 million closed in early October, another $12.5 million is available when Hicuity Health closes, and $25 million more is available subject to maintaining $130 million in Mobile Health revenue. DocGo also has about $19 million of old municipal receivables it is trying to collect—$6.7 million imminently and $12.6 million late this year or early 2027.Effective net cash The balance sheet is no longer a back-office detail. Liabilities to assetsAnd then there is the management vacuum.

Today, we announced that I'll be transitioning out of my role as CEO of DocGo upon the appointment of my successor... I plan to stay on until at least March 31, 2027, and will work closely with the board on an orderly transition.

Lee Bienstock, Chief Executive Officer · 2026-11-09
Board member Michael Burdiek described the search as looking for operational wherewithal and someone who has been through restructuring and turnaround situations. That is not a growth-CEO profile. It is a workout-CEO profile. Norm Rosenberg also declined to give 2027 guidance: “We specifically did not issue guidance for 2027 in this call... we would anticipate seeing some positive adjusted EBITDA” — Norman Rosenberg, Chief Financial Officer · 2026-11-09.

Hicuity, RPM, and the regulatory flip

The odd part of the keyword map is that Hicuity Health was the company's No. 1 keyword last quarter. This quarter it does not appear in the top 30, even though the deal is expected to close later this month or early next month and is tied to the second $12.5 million tranche. The market's attention has moved from the strategic logic of the acquisition to the financing around it. Prior management said the gating factor was state regulatory approvals: “Obviously you need to get state regulatory approvals, which we think should not be much of an issue other than timing, because that is always unpredictable.” — Norm Rosenberg, Chief Financial Officer · 2026-08-17 On this call Lee said simply that nothing is slipping.The more interesting new keyword is Fee Schedule, which jumped into the top five. A year ago, the RPM story was a regulatory risk: “CMS has got a proposed rule out there that might limit or eliminate Medicare reimbursement for RPM in 2027.” — Ryan MacDonald, Analyst · 2026-08-17 Lee's answer then was that the vast majority of DocGo's roughly 55,000 monitored patients were cardiac patients with implantable devices, not the kind of monitoring under discussion. This quarter the framing flipped. CMS is requiring a physician visit to enroll a patient in RPM, and DocGo can provide both the visit and the monitoring. “You simply cannot enroll a patient without also having a medical visit... we have the ability to do both, and we think that is a benefit for us and a positive.” — Lee Bienstock, Chief Executive Officer · 2026-11-09 That is a genuine potential moat around patient monitoring, though it is still a small revenue line—roughly $16 million-$17 million for 2026.Globally, the market is rewarding site of service shifts—care moving out of hospitals and into lower-cost settings. DocGo sits on the right side of that wave with its care-in-the-home and mobile phlebotomy assets. But at a $25 million market cap, it is too small to be a market proxy and too balance-sheet-constrained to be a pure play.

Bottom line

DocGo is no longer a growth story. It is a liquidation-adjacent turnaround: shrink the revenue base, cut SG&A, lift gross margin, collect old receivables, close Hicuity, and hope the cash lasts until the business crosses into positive EBITDA. The Q3 numbers show real progress—gross margin and SG&A are close to management's roughly $80 million revenue, mid-30s gross margin, $28 million SG&A breakeven model. But the company still guides to a $17 million-$22 million EBITDA loss for 2026, revenue guidance came down, and the CEO is leaving.The prior calls promised EBITDA breakeven exiting 2026. “EBITDA breakeven exiting 2026. Can you maybe just talk a little bit about how you're going to get there? It was a pretty significant loss in the quarter here.” — David Larsen, Analyst · 2026-08-17 This one reaffirms it, but with a smaller top line and a new CEO search. Price to revenue Until the receivables arrive and Hicuity closes, the equity is a call option on the pruning being enough. The market is not paying up for that option.